Sapient Capital’s Akebia Therapeutics AKBA Stock Holding History

Sapient Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200,000	Closed	-$278K	–	401
2026 Q1	$278K	Hold	200,000	–	–	﹤0.01%	367
2025 Q4	$318K	Hold	200,000	–	–	﹤0.01%	330
2025 Q3	$542K	Hold	200,000	–	–	0.01%	253
2025 Q2	$728K	Hold	200,000	–	–	0.01%	219
2025 Q1	$384K	Hold	200,000	–	–	0.01%	264
2024 Q4	$380K	Hold	200,000	–	–	0.01%	271
2024 Q3	$264K	Hold	200,000	–	–	0.01%	336
2024 Q2	$204K	Hold	200,000	–	–	﹤0.01%	349
2024 Q1	$366K	Hold	200,000	–	–	0.01%	268
2023 Q4	$248K	Buy	+200,000	New	+$204K	0.01%	335

Other funds holding AKBA

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

EWS

Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Sapient Capital's AKBA Position: Q2 2026 in Review

Sapient Capital sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 200,000 shares — an estimated $278K sold.

Sapient Capital first reported a position in AKBA in Q4 2023 and held it in 10 quarters. The position peaked at $728K in Q2 2025. 9 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

Sapient Capital reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
Sapient Capital sold 200,000 Akebia Therapeutics shares in Q2 2026, an estimated $278K.
Sapient Capital first reported a position in Akebia Therapeutics in Q4 2023 and held it in 10 quarters.
Sapient Capital's Akebia Therapeutics position peaked at $728K in Q2 2025.
9 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.